Preparation and valuation of a topical solution containing eutectic mixture of itraconazole and phenol

[1]  Juyoung Kim,et al.  Phase behavior of itraconazole-phenol mixtures and its pharmaceutical applications. , 2012, International journal of pharmaceutics.

[2]  V. P. Sousa,et al.  Erratum to: A Novel Transdermal Delivery System for the Anti-Inflammatory Lumiracoxib: Influence of Oleic Acid on In Vitro Percutaneous Absorption and In Vivo Potential Cutaneous Irritation , 2010, AAPS PharmSciTech.

[3]  S. Akhter,et al.  Microemulsion as a Potential Transdermal Carrier for Poorly Water Soluble Antifungal Drug Itraconazole , 2009 .

[4]  M. Aqil,et al.  Status of fatty acids as skin penetration enhancers-a review. , 2009, Current drug delivery.

[5]  B. Zhou,et al.  Preparation and evaluation of itraconazole dihydrochloride for the solubility and dissolution rate enhancement. , 2009, International journal of pharmaceutics.

[6]  Yukio Kato,et al.  P-glycoprotein (Abcb1) is involved in absorptive drug transport in skin. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[7]  W. Lu,et al.  Development and evaluation of novel itraconazole-loaded intravenous nanoparticles. , 2008, International journal of pharmaceutics.

[8]  Emily F. Smith,et al.  Physical stability of ternary solid dispersions of itraconazole in polyethyleneglycol 6000/hydroxypropylmethylcellulose 2910 E5 blends. , 2008, International journal of pharmaceutics.

[9]  Chong-K. Kim,et al.  Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  Hongzhuo Liu,et al.  Gelatin-stabilised microemulsion-based organogels facilitates percutaneous penetration of Cyclosporin A in vitro and dermal pharmacokinetics in vivo. , 2007, Journal of pharmaceutical sciences.

[11]  G. Stagni,et al.  Effects of penetration enhancers on in vitro permeability of meloxicam gels. , 2007, International journal of pharmaceutics.

[12]  M. Rashidi,et al.  The effect of terpene concentrations on the skin penetration of diclofenac sodium. , 2007, International journal of pharmaceutics.

[13]  Dae-Duk Kim,et al.  Formulations of Itraconazole for Topical Skin Delivery , 2007 .

[14]  Thomas J Walsh,et al.  Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. , 2004, The New England journal of medicine.

[15]  T. Nabeshima,et al.  Intracutaneous Distributions of Fluconazole, Itraconazole, and Griseofulvin in Guinea Pigs and Binding to Human Stratum Corneum , 2004, Antimicrobial Agents and Chemotherapy.

[16]  M. Seishima,et al.  Distribution of an antifungal drug, itraconazole, in pathological and non-pathological tissues. , 2004, European journal of dermatology : EJD.

[17]  U. Schäfer.  ?Dermatological and Transdermal Formulations?Kenneth A. Walters (Editor), Marcel Dekker, New York, Basel; 2002, 567 pages, US$dollar; 195; ISBN 0-8247-9889-9 , 2003 .

[18]  K. A. Walters,et al.  Dermatological And Transdermal Formulations , 2002 .

[19]  A. Nokhodchi,et al.  The effect of surfactants on the skin penetration of diazepam. , 2001, International journal of pharmaceutics.

[20]  D. Nesseem.  Formulation and evaluation of itraconazole via liquid crystal for topical delivery system. , 2001, Journal of pharmaceutical and biomedical analysis.

[21]  I. Alberti,et al.  In vivo assessment of enhanced topical delivery of terbinafine to human stratum corneum. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[22]  M. Oris,et al.  Activities of an Intravenous Formulation of Itraconazole in Experimental Disseminated Aspergillus, Candida, and Cryptococcus Infections , 2000, Antimicrobial Agents and Chemotherapy.

[23]  D. Jones,et al.  Rheological, mechanical and membrane penetration properties of novel dual drug systems for percutaneous delivery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[24]  K. H. Lee,et al.  Absorption, first-pass metabolism, and disposition of itraconazole in rats. , 2000, Chemical & pharmaceutical bulletin.

[25]  J. Leyden.  Pharmacokinetics and pharmacology of terbinafine and itraconazole. , 1998, Journal of the American Academy of Dermatology.

[26]  B. E. Cohen,et al.  Amphotericin B toxicity and lethality: a tale of two channels , 1998 .

[27]  B. W. Barry,et al.  Transdermal delivery from eutectic systems: enhanced permeation of a model drug, ibuprofen. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[28]  E. Touitou,et al.  Testosterone skin permeation enhancement by menthol through formation of eutectic with drug and interaction with skin lipids. , 1997, Journal of pharmaceutical sciences.

[29]  S. Redding,et al.  Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. , 1996, The Journal of infectious diseases.

[30]  B. Elewski,et al.  Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. Guidelines/Outcomes Committee. American Academy of Dermatology. , 1996, Journal of the American Academy of Dermatology.

[31]  E. Touitou,et al.  Chiral β-blockers for transdermal delivery , 1994 .

[32]  Raymond C Rowe,et al.  Handbook of Pharmaceutical Excipients , 1994 .

[33]  D. Roseeuw,et al.  New approaches to the treatment of onychomycosis. , 1993, Journal of the American Academy of Dermatology.

[34]  J. V. van Cutsem,et al.  Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis. , 1992, Journal of the American Academy of Dermatology.

[35]  R. Woestenborghs,et al.  Itraconazole penetrates the nail via the nail matrix and the nail bed—an investigation in onychomycosis , 1991, Clinical and experimental dermatology.

[36]  Adrian C. Williams,et al.  Essential oils as novel human skin penetration enhancers , 1989 .

[37]  R. Woestenborghs,et al.  The Clinical Pharmacokinetics of Itraconazole: An Overview , 1989, Mycoses.

[38]  R. Hay,et al.  First International Symposium on Itraconazole: A Summary , 1987 .

[39]  J. V. van Cutsem,et al.  Itraconazole, a new triazole that is orally active in aspergillosis , 1984, Antimicrobial Agents and Chemotherapy.

[40]  S. Riegelman,et al.  Pharmaceutical applications of solid dispersion systems. , 1971, Journal of pharmaceutical sciences.

[41]  John H. Draize,et al.  METHODS FOR THE STUDY OF IRRITATION AND TOXICITY OF SUBSTANCES APPLIED TOPICALLY TO THE SKIN AND MUCOUS MEMBRANES , 1944 .